Citigroup’s Cardiol Therapeutics CRDL Stock Holding History

Citigroup’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-792	Closed	-$1K	–	5893
2022 Q2	$1K	Buy	+792	New	+$1.13K	﹤0.01%	5996

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MHIC

Marble Harbor Investment Counsel Boston, Massachusetts $923M AUM 14.09% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Citigroup's CRDL Position: Q3 2022 in Review

Citigroup sold out of Cardiol Therapeutics (CRDL) in Q3 2022, closing a stake of 792 shares — an estimated $1K sold.

Citigroup first reported a position in CRDL in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 26 funds tracked by Wall St. Rank hold CRDL as of Q3 2022.

Citigroup reported no remaining Cardiol Therapeutics position as of Q3 2022 after selling out during the quarter.
Citigroup sold 792 Cardiol Therapeutics shares in Q3 2022, an estimated $1K.
Citigroup first reported a position in Cardiol Therapeutics in Q2 2022 and held it in 1 quarter.
Citigroup's Cardiol Therapeutics position peaked at $1K in Q2 2022.
26 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.